Anti-IL-4,13 strategy in management of comormid patients in the regional register of severe bronchial asthma
- Authors: Naumova V.V.1, Kiseleva D.V.1, Beltyukov E.K.1, Starikova Y.R.1
-
Affiliations:
- Ural State Medical University
- Issue: Vol 19, No 4 (2022)
- Pages: 435-446
- Section: Original studies
- URL: https://journals.rcsi.science/raj/article/view/253251
- DOI: https://doi.org/10.36691/RJA1580
- ID: 253251
Cite item
Abstract
BACKGROUND: T2 inflammation underlies bronchial asthma and inflammatory nasal diseases, supporting the concept of a “united airway disease.” Dupilumab, by blocking interleukin-4 and -13 receptors, can improve the clinical and functional parameters and life quality of comorbid patients with T2 diseases.
AIM: To evaluate efficacy of anti-IL4R,13 therapy in patients with severe asthma with chronic inflammatory nasal diseases in real clinical practice.
MATERIALS AND METHODS: The study of dupilumab efficacy was conducted by comparing related populations based on a regional register of patients with severe asthma and concomitant chronic inflammatory nasal diseases. Asthma control achievement and decrease in the rate of patients with uncontrolled asthma were assessed as primary endpoint. The need for bronchodilators and systemic glucocorticosteroids, number of asthma exacerbations, emergency calls and hospitalizations, AQLQ scores, level of peripheral blood eosinophils, and respiratory function were also assessed. Nasal symptoms were assessed using SNOT-22 and VAS. A subgroup analysis of ACT scores was performed depending on chronic inflammatory nasal disease phenotypes.
RESULTS: Within 12 months of dupilumab therapy, ACT increased from 11 (Q1–Q3: 7–13) to 20 (Q1–Q3: 18–24) points (p <0.001). The rate of patients with partially and fully controlled asthma increased from 0 to 57.9% (p <0.001). The need for bronchodilators decreased from 17.5 doses per week (Q1–Q3: 5.8–24.5) to 1.0 (Q1–Q3: 0.0–2.2) (p <0.001). Before the dupilumab therapy, 68.5% of the patients took systemic corticosteroids and, after 12 months, 10.5% of patients (p <0.001). The number of asthma exacerbations decreased from 2.19±1.83 (95% CI 1.28–3.11) to 0.22±0.55 (0.05–0.49) (p <0.001) and hospitalizations from 1.00±1.27 (95% CI 0.37–1.63) to 0.17±0.51 (95% CI 0.09–0.42) (p <0.001). AQLQ scores increased from 2.91 (Q1–Q3: 2.43–3.86) to 5.89 points (Q1–Q3: 4.70–6.58) (p <0.001). The volume of forced exhalation in 1 sec increased from 55.38%±16.66% (95% CI 47.10–63.67) to 81.5%±19.14% (95% CI 71.98–91.02) (p <0.001). SNOT-22 scores decreased from 47±29 (95% CI 34–61) to 25±18 (95% CI 17–34) points (p <0.001) and the VAS score from 7±2 (95% CI 6–8) to 4±2 (95% CI 3–5) (p <0.001).
CONCLUSIONS: Dupilumab improved asthma and nasal symptoms control, improved quality of life and respiratory function, and reduce asthma exacerbations and hospitalizations. Patients with severe asthma and comorbid allergic rhinitis and chronic rhinosinusitis with polyps responded better to dupilumab therapy than patients with chronic rhinosinusitis without polyps.
Full Text
##article.viewOnOriginalSite##About the authors
Veronika V. Naumova
Ural State Medical University
Author for correspondence.
Email: nika.naumova@gmail.com
ORCID iD: 0000-0002-3028-2657
SPIN-code: 8210-6478
MD, Cand. Sci. (Med.)
Russian Federation, EkaterinburgDarina V. Kiseleva
Ural State Medical University
Email: darinakiseljova@mail.ru
ORCID iD: 0000-0002-7847-5415
SPIN-code: 9446-7866
MD
Russian Federation, EkaterinburgEvgeny K. Beltyukov
Ural State Medical University
Email: asthma@mail.ru
ORCID iD: 0000-0003-2485-2243
SPIN-code: 6987-1057
MD, Dr. Sci. (Med.), Professor
Russian Federation, EkaterinburgYana R. Starikova
Ural State Medical University
Email: yana.shakirova.1997@bk.ru
MD
Russian Federation, EkaterinburgReferences
- Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines--Recommendations for severe asthma. Allergy. 2021; 76(1):14–44. doi: 10.1111/all.14425
- Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: Clinical impact and management. Respirology. 2017;22(4):651–661. doi: 10.1111/resp.13026
- Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy. 2021;76(8):2337–2353. doi: 10.1111/all.14809
- Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol. 2021;9(3): 1133–1141. doi: 10.1016/j.jaip.2020.09.063
- Beltyukov ЕK, Shelyakin VA, Naumova VV, et al. Organization of immunobiological therapy for severe bronchial asthma in the Sverdlovsk region. Russian Journal of Allergy. 2021;18(1):6–17. doi: https://doi.org/10.36691/RJA1414
- Naumova VV, Beltyukov EK, Kiseleva DV. Efficacy of anti-IL-5 therapy with mepolizumab for severe bronchial asthma and concomitant inflammatory nasal diseases in real clinical practice. Russian Journal of Allergy. 2022;19(1):67–79. doi: https://doi.org/10.36691/RJA1519
- Allergic rhinitis. Clinical recommendations. The Russian Association of Allergology and Clinical Immunology; 2018. (In Russ). Available from: https://nrcii.ru/docs/2.allergic_rhinitis.pdf. Accessed: 28.10.2022.
- Allergic rhinitis. Clinical recommendations. The Russian Association of Allergology and Clinical Immunology, National Medical Association of Otorhinolaryngologists, The Union of Pediatricians of Russia; 2020. (In Russ). Available from: https://cr.minzdrav.gov.ru/ recomend/261_1. Accessed: 28.10.2022.
- Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013; 368(26):2455–2466. doi: 10.1056/NEJMoa1304048
- Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi: 10.1016/S0140-6736(16)30307-5
- Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; 378(26):2486–2496. doi: 10.1056/NEJMoa1804092
- Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. doi: 10.1016/j.jaip.2019.08.050
- Rabe KF, Nair P, brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi: 10.1056/NEJMoa1804093
- Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): An open-label extension study. Lancet Respir Med. 2022;10(1):11–25. doi: 10.1016/S2213-2600(21)00322-2
- Carpagnano GE, Scioscia G, Buonamico E, et al. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management. Multidiscip Respir Med. 2022;17(1):797 doi: 10.4081/mrm.2022.797
- Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. doi: 10.1111/cea.13614
- Mümmler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Allergy Clin Immunol Pract. 2021;9(3):1177–1185.e4. doi: 10.1016/j.jaip.2020.09.014